What does TP53 mutation mean for Colorectal Cancer prognosis

TP53 Mutations in Colorectal Cancer: What You Should Know

I appreciate your question about TP53 mutations. However, I need to be transparent: the NCCN Guidelines for Colorectal Cancer that I have access to do not currently include TP53 as a standard biomarker for prognostic or treatment decision-making in colorectal cancer.

This is an important distinction. Let me explain what this means and what we do know:

What TP53 Does (The Biology)

TP53 is a tumor suppressor gene—think of it as a "brake" on cell growth. When functioning normally, TP53 helps prevent cells from becoming cancerous. When mutated, this protective function is lost, which can allow cancer cells to grow more aggressively.

What's Currently Recommended for CRC Testing

According to NCCN Guidelines for Colon Cancer (Version 5.2025), the standard biomarkers that ARE tested and guide treatment decisions include:

• KRAS and NRAS mutations – predict response to certain targeted therapies
• BRAF mutations – affect prognosis and treatment options
• MMR/MSI status – determines eligibility for immunotherapy
• HER2 amplification – identifies patients for HER2-targeted therapy
• NTRK fusions – identifies patients for TRK inhibitors
• POLE/POLD1 mutations – predicts immunotherapy benefit

Why TP53 Isn't Currently in Standard Guidelines

While TP53 mutations are common in colorectal cancer and may have biological significance, the NCCN Panel has not yet incorporated TP53 testing into routine clinical recommendations because:

1. Limited predictive value – It hasn't been shown to reliably predict which treatments will work best
2. Prognostic uncertainty – The relationship between TP53 status and outcomes isn't clear enough for clinical decision-making
3. Research ongoing – This is an active area of investigation

What This Means for You

If your pathology report mentions a TP53 mutation:

• This is informational but doesn't currently change standard treatment recommendations
• Your oncologist will focus on the biomarkers listed above (KRAS, BRAF, MMR/MSI, etc.) to guide therapy
• TP53 status may be relevant in clinical trials or research settings

Questions to ask your oncologist:

1. "Does my tumor have any of the standard biomarkers tested (KRAS, BRAF, MMR/MSI, HER2)?"
2. "If TP53 was tested, does this change my treatment plan?"
3. "Are there any clinical trials that specifically look at TP53-mutant colorectal cancers?"
4. "Should I have my tumor tested for other emerging biomarkers?"

The Bottom Line

TP53 mutations are common in colorectal cancer, but they're not yet part of the standard decision-making framework. Your treatment will be guided by the biomarkers that NCCN Guidelines recommend—particularly KRAS/NRAS, BRAF, and MMR/MSI status. As research evolves, TP53 may become more clinically relevant in the future.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.